Advantest Corp (ATE)

12.61
0.53 4.37
OTC : Technology
Prev Close 12.08
Open 12.60
Day Low/High 12.59 / 12.62
52 Wk Low/High 7.01 / 12.08
Volume 4.21K
Avg Volume 20.40K
Exchange OTC
Shares Outstanding 174.57M
Market Cap 1.71B
EPS 0.62
P/E Ratio N/A
Div & Yield 0.16 (1.70%)
Advantest Develops "Hadatomo™" Photoacoustic Microscope For Non-Invasive Imaging Of Blood Vessels In The Dermis To A Depth Of 3mm New Instrument Further Enables Critical Research In Dermatology And Regenerative Science

Advantest Develops "Hadatomo™" Photoacoustic Microscope For Non-Invasive Imaging Of Blood Vessels In The Dermis To A Depth Of 3mm New Instrument Further Enables Critical Research In Dermatology And Regenerative Science

Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857, NYSE:ATE) announced that it has developed a new photoacoustic microscope that enables non-invasive imaging of blood vessels in the dermis to a...

Antibe Therapeutics Reports Q1 2016 Interim Financial And Operating Results And A Further Update On Its Validation Studies

Antibe Therapeutics Reports Q1 2016 Interim Financial And Operating Results And A Further Update On Its Validation Studies

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, August 21 for the fiscal quarter ended June 30, 2015.

Antibe Announces Completion Of Phase I Studies Of ATB-346 And An Update On Its Validation Studies

Antibe Announces Completion Of Phase I Studies Of ATB-346 And An Update On Its Validation Studies

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that the report on their Phase I studies of ATB-346, its lead drug, has been finalized.

Antibe Therapeutics Reports Year-End Financial And Operating Results

Antibe Therapeutics Reports Year-End Financial And Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results today for the fourth quarter and the year ended March 31, 2015.

Advanced Mask Technology Center GmbH & Co. KG (AMTC) Rates Advantest As Best Supplier In 2014

Advanced Mask Technology Center GmbH & Co. KG (AMTC) Rates Advantest As Best Supplier In 2014

Leading semiconductor equipment supplier Advantest Corporation (TSE:6857, NYSE:ATE) has had the honor of being named AMTC's Best Supplier for 2014.

W2BI Introduces Automated Tests Based On CTIA's Battery Life Test Plan For UE Acceptance Using Keysight's UXM Wireless Test Set

W2BI Introduces Automated Tests Based On CTIA's Battery Life Test Plan For UE Acceptance Using Keysight's UXM Wireless Test Set

W2BI, Inc., an Advantest Group company and a global leader in wireless device test automation products, and Keysight Technologies, a global electronic measurement technology leader, announced the availability of a battery...

Advantest Files Annual Report Form 20-F With The SEC For The Year Ended March 31, 2015

Advantest Files Annual Report Form 20-F With The SEC For The Year Ended March 31, 2015

Advantest Corporation (TSE: 6857, NYSE: ATE) has filed its annual report Form 20-F for the year ended March 31, 2015 with the Securities and Exchange Commission.

Advantest Develops Semiconductor Circuit Analysis Terahertz Technology

Advantest Develops Semiconductor Circuit Analysis Terahertz Technology

Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857, NYSE: ATE) announced today that it has developed a technology utilizing short-pulse terahertz waves for analysis of electrical circuits.

Advantest Recognized As A Top Semiconductor Test Equipment Supplier For 27th Consecutive Year

Advantest Recognized As A Top Semiconductor Test Equipment Supplier For 27th Consecutive Year

Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857, NYSE: ATE) has once again been named to VLSIresearch's coveted 10 BEST list, securing the company its 27th consecutive year as a top-rated...

Advantest To Install F7000 E-Beam Lithography System To Support Imec's Advanced Semiconductor R&D

Advantest To Install F7000 E-Beam Lithography System To Support Imec's Advanced Semiconductor R&D

Advantest Corporation (TSE: 6857, NYSE: ATE) May 19, 2015 - Leading semiconductor equipment supplier Advantest Corporation announces that imec has selected its leading-edge F7000 electron-beam lithography system for...

Antibe Therapeutics Announces Additional Validation Data On ATB-346

Antibe Therapeutics Announces Additional Validation Data On ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE) announced today the results of additional testing of the in vivo activity of its lead anti-inflammatory drug, ATB-346.

Antibe Therapeutics Provides An Update On Its Data Review And Corporate Strategy

Antibe Therapeutics Provides An Update On Its Data Review And Corporate Strategy

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) announced today that it has completed the process of collecting and reviewing its Phase I data, further to its January 16, 2015 press release.

Advantest To Exhibit Terahertz Spectroscopy And Imaging Technology At PITTCON In New Orleans, LA, March 9-12, 2015

Advantest To Exhibit Terahertz Spectroscopy And Imaging Technology At PITTCON In New Orleans, LA, March 9-12, 2015

Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857, NYSE: ATE) will demonstrate its latest TAS7500 THz spectroscopy and imaging systems and solutions at the annual PITTCON Conference and Expo, to...

Antibe Therapeutics Reports Q3 2015 Interim Financial And Operating Results And Director Resignation

Antibe Therapeutics Reports Q3 2015 Interim Financial And Operating Results And Director Resignation

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results today for the fiscal quarter ended December 31, 2014.

W2BI, Inc. To Demonstrate Suite Of New Wireless Device Test Automation Products At Mobile World Congress In Barcelona, March 2-5, 2015

W2BI, Inc. To Demonstrate Suite Of New Wireless Device Test Automation Products At Mobile World Congress In Barcelona, March 2-5, 2015

W2BI, Inc., a member of the Advantest Group (TSE:6857) (NYSE:ATE), and a leading software provider of wireless device test automation products for the world's top mobile operators and suppliers, announced that it will...

Antibe Therapeutics Announces No Material Change

Antibe Therapeutics Announces No Material Change

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF), wishes to confirm that its management is not aware of any corporate development or undisclosed material change to the Company or its operations that would...

Antibe Therapeutics Suspends Its Phase I Clinical Trial Due To Safety Concerns

Antibe Therapeutics Suspends Its Phase I Clinical Trial Due To Safety Concerns

Antibe Therapeutics Inc. (TSXV:ATE; OTCQX:ATBPF) today announced that it has suspended development of its lead drug, ATB-346, due to safety concerns encountered in its Phase I clinical trial.

Advantest (ATE) Upgraded From Sell to Hold

Advantest (ATE) Upgraded From Sell to Hold

Advantest (ATE) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATE, MVNR Downgrades: EBF, HBHC, KOF, UBNT, VEEV Initiations: KFX, SWH, XNCR Read on to get TheStreet Quant Ratings' detailed report:

Antibe Therapeutics Announces Appointment Of Canadian Rheumatologist J. Carter Thorne To Its Clinical Advisory Board

Antibe Therapeutics Announces Appointment Of Canadian Rheumatologist J. Carter Thorne To Its Clinical Advisory Board

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE; OTCQX:ATBPF) is pleased to announce the expansion of its Clinical Advisory Board with the appointment of Canadian rheumatologist J.

Antibe Therapeutics Announces Appointment Of US-Based Investor Relations Consultant

Antibe Therapeutics Announces Appointment Of US-Based Investor Relations Consultant

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV: ATE, OTCQX: ATBPF) today announced that they have, subject to approval by securities regulators, entered into an Investor Relations Consulting Agreement with...

Antibe Therapeutics Provides Update On Its Acute Pain Drug ATB-352

Antibe Therapeutics Provides Update On Its Acute Pain Drug ATB-352

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV: ATE; OTCQX: ATBPF) is pleased to report results from animal proof-of-concept studies on ATB-352, which is the second drug in the Company's pipeline, as...

Advantest To Exhibit Terahertz Spectroscopy And Imaging Systems At AAPS In San Diego, CA November 3-5, 2014

Advantest To Exhibit Terahertz Spectroscopy And Imaging Systems At AAPS In San Diego, CA November 3-5, 2014

Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) (NYSE: ATE) will promote its new TAS7500 THz spectroscopy and imaging systems at the AAPS annual meeting.

Advantest To Exhibit At IMAPS 2014, San Diego, CA, October 14-16

Advantest To Exhibit At IMAPS 2014, San Diego, CA, October 14-16

Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857, NYSE: ATE) will promote its new TS9000 mold thickness analysis solutions at the International Microelectronics Assembly and Packaging...

Antibe Therapeutics Completes Single Ascending Dose Portion Of ATB-346 Phase I Program

Antibe Therapeutics Completes Single Ascending Dose Portion Of ATB-346 Phase I Program

Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE; OTCQX:ATBPF) is pleased to report that the pre-scheduled single ascending dose portion of its Phase I program has been completed and...

Antibe Therapeutics Reports On Results Of AGM Voting

Antibe Therapeutics Reports On Results Of AGM Voting

Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE; OTCQX:ATBPF) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders of the ...

Advantest Launches TS9000 System For Semiconductor Packaging Inspection

Advantest Launches TS9000 System For Semiconductor Packaging Inspection

Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857, NYSE:ATE) announced today that a new mold thickness metrology system, the TS9000, for measuring the thickness of semiconductor packaging,...

Advantest To Exhibit And Present At FACSS SciX 2014, September 28-October 3, 2014, Reno, NV

Advantest To Exhibit And Present At FACSS SciX 2014, September 28-October 3, 2014, Reno, NV

Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857, NYSE: ATE) will promote its TAS7500 family of compact and multipurpose terahertz spectroscopic / imaging systems at SCIX (The Great...

Antibe Therapeutics Commences Trading On The US OTCQX Marketplace

Antibe Therapeutics Commences Trading On The US OTCQX Marketplace

Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that, as of today, common shares of the Corporation began trading in the United States on the...

Advantest To Exhibit And Present At IRMMW-THz Conference, Tucson, Arizona, September 14-19, 2014

Advantest To Exhibit And Present At IRMMW-THz Conference, Tucson, Arizona, September 14-19, 2014

Leading semiconductor test equipment supplier Advantest Corporation (TSE:6857, NYSE:ATE) will promote its new TAS7500TS THZ wave spectroscopy and analysis platform at the International Conference on Infrared,...